We are extremely grateful for the comments by Drs Maisels and Newman1 concerning our report2 on the effect of neonatal blue-light phototherapy on dysplastic nevus development, and we are happy to respond to their questions. Drs Maisels and Newman questioned how the study population had been selected and how the data regarding the neonatal history of the children had been obtained. Our study was conducted in 2 secondary schools on an unselected study population of 14to 18-year-olds. Each subject underwent a whole-body examination, excluding the scalp and the anogenital area. Before the start of the survey, a standardized diagnostic protocol was defined for the identification of common acquired and clinically atypical melanocytic nevi. After the clinical examination, a standardized questionnaire was completed by all the students in consultation with their parents. The questionnaire data concerning the neonatal history of the children were compared with the official neonatal medical charts to validate our results. Drs Maisels and Newman also raise the very important question of the light source used for the treatment of neonatal jaundice in Hungary in the 1980s. Blue-light phototherapy has been used in Hungary to reduce the plasma concentration of bilirubin for decades. The spectrum of the blue-light lamp is between 370 and 600 nm, with a maximum at 450 nm. Approximately 0.3% of the emitted light comprises UV-A radiation. We agree that a notably high proportion of the newborns in Hungary received neonatal phototherapy as compared with those in the United States. It is our opinion that it would be advisable to define a more restricted treatment protocol to rule out the unnecessary application of blue-light phototherapy and thereby prevent the potential adverse effects.